Hong Kong – CF PharmTech, Inc. (stock code: 02652) announced that the National Medical Products Administration (NMPA) has formally accepted the Investigational New Drug (IND) application for its proprietary long-acting inhalation-powder candidate ICF001. The filing covers six acceptance numbers (CXHL2600306/07/08/09/10/11) and was submitted by CF PharmTech Guangzhou Limited and the parent company.
ICF001, classified as a Class 2.1 chemical drug, employs a prodrug platform designed to deliver the active molecule deeply into lung tissue. Post-inhalation, endogenous lung enzymes gradually cleave the prodrug, moderating the initial peak plasma concentration and extending local exposure—an approach expected to optimize pharmacokinetics and improve patient tolerability.
Initial clinical development will target: • Pulmonary arterial hypertension (PAH; WHO Group 1), a life-threatening rare disease. • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), a larger population with limited therapeutic options.
Pre-clinical data suggest that the same biological pathway may also confer anti-fibrotic benefits, potentially enabling future expansion into idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and related indications.
Strategically, CF PharmTech aims to: 1. Enhance drug-loading efficiency to lower dosing burden and improve airway tolerability. 2. Achieve controlled systemic exposure while maintaining therapeutic lung concentrations, thereby facilitating flexible, titratable dosing regimens.
Management views the IND acceptance as a key milestone in advancing its high-barrier respiratory pipeline. The company will continue liaising with the NMPA to initiate clinical trials in accordance with regulatory requirements.
Risk disclosure: IND acceptance is an administrative step and does not guarantee marketing approval. Drug development involves significant scientific and regulatory uncertainties; investors should exercise caution when dealing in CF PharmTech securities.